CureVac (NASDAQ:CVAC) Downgraded to Hold Rating by UBS Group

UBS Group downgraded shares of CureVac (NASDAQ:CVAC - Free Report) from a strong-buy rating to a hold rating in a research note released on Thursday, MarketBeat reports. They currently have $5.50 price target on the stock, down from their previous price target of $12.00.

A number of other brokerages also recently issued reports on CVAC. Jefferies Financial Group reaffirmed a "hold" rating and set a $5.00 price target (down from $7.00) on shares of CureVac in a report on Friday, June 13th. Citigroup lowered CureVac to a "market perform" rating in a research report on Thursday, June 12th. Citizens Jmp downgraded shares of CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $10.00 price target on shares of CureVac in a research note on Wednesday, May 28th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $6.83.

CureVac Stock Down 0.4%

CureVac stock traded down $0.02 during trading hours on Thursday, hitting $5.38. The stock had a trading volume of 770,383 shares, compared to its average volume of 811,223. The company has a quick ratio of 7.64, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.21 billion, a P/E ratio of 5.85 and a beta of 2.49. CureVac has a 12-month low of $2.37 and a 12-month high of $5.72. The stock's 50-day moving average price is $4.24 and its 200-day moving average price is $3.65.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a net margin of 35.44% and a return on equity of 30.89%. Equities research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CVAC. Signaturefd LLC increased its stake in shares of CureVac by 29.2% in the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company's stock worth $123,000 after purchasing an additional 8,170 shares in the last quarter. Geode Capital Management LLC grew its holdings in CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock valued at $824,000 after purchasing an additional 22,491 shares during the period. Quadrant Capital Group LLC increased its position in CureVac by 61.8% in the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock worth $171,000 after buying an additional 19,098 shares in the last quarter. Barclays PLC raised its stake in shares of CureVac by 51.8% in the fourth quarter. Barclays PLC now owns 34,836 shares of the company's stock worth $118,000 after buying an additional 11,890 shares during the period. Finally, XTX Topco Ltd lifted its position in shares of CureVac by 90.2% during the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock valued at $83,000 after buying an additional 11,553 shares in the last quarter. Hedge funds and other institutional investors own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.